Efficacy of different doses of oliceridine for Patient-Controlled Intravenous Analgesia in patients undergoing Total Laparoscopic Hysterectomy
- 1Department of Anesthesiology, First Affiliated Hospital of Shihezi University School of Medicine, Shihezi, China
- 2Department of Anesthesiology, The Cancer Hospital Affiliated to Chongqing University, Chongqing, China
Abstract
Objective: To evaluate the efficacy and safety of three oliceridine different doses for oliceridine for patient-controlled analgesia (PCIA) in patients undergoing during total laparoscopic hysterectomy, following the premature termination of the planned sufentanil control arm. Methods: This prospective, randomized, double-blind trial was originally designed as a four-arm study. Due to operational challenges in patient recruitment and randomization within the single-center setting-specifically, significant reluctance among eligible patients to be randomized to receive a traditional opioid regimen when oliceridine was available, leading to unsustainable enrollment timelines—the sufentanil control arm was prematurely terminated. The final analysis therefore focused on three oliceridine doses: 0.1, 0.35, and 0.5 mg/kg, diluted to 100 ml with normal saline for 48-hour PCIA. The primary endpoint for sample size calculation was the incidence of postoperative nausea and vomiting (PONV) at 24 h. Efficacy and safety outcomes analyzed included: NRS pain scores (at rest and during cough), Ramsay sedation scores, incidence of rescue analgesia, various recovery indicators (time to first flatus, time to ambulation, QoR-15 scores), and opioid-related adverse events. Results: Compared to the low-dose group, the moderate- and high-dose groups demonstrated significant improvements in cough-pain scores and bolus press attempts (“Bolus press attempts” were defined as the total number of patient-initiated demands for a supplemental dose, including attempts made within the lockout interval) (p < 0.0083). Further comparison revealed that the moderate-dose group showed the best recovery outcomes, including shorter time to first flatus and ambulation, and higher QoR-15 scores. In contrast, although the high-dose group provided more potent analgesia, it was associated with a higher incidence of nausea, delayed flatus, and a significantly lower quality of recovery (QoR-15) score at 48 hours postoperatively compared to the moderate-dose group (p < 0.0083). Conclusion: Within the investigated PCA oliceridine dose range, the 0.35 mg/kg dose promotes early recovery in patients undergoing laparoscopic total hysterectomy through effective analgesia and reduced nausea, representing the best balance between efficacy and safety among the tested oliceridine-specific regimens.
Related
- Comparison of remimazolam total intravenous anesthesia versus sevoflurane inhalational anesthesia on emergence agitation in patients undergoing laparoscopic surgery for gastric or colorectal cancer: study protocol for a randomized controlled trial
- Two-period demand phenotypes of oliceridine-based patient-controlled intravenous analgesia after gynecologic surgery: perioperative correlates of persistent high demand.
- Comparison of Postoperative Analgesic Efficacy Between Opioid-free Anaesthesia Using Intravenous Magnesium, Lidocaine, and Erector Spinae Plane Block, and Opioid-based Anaesthesia in Laparoscopic Abdominal Surgeries: A Randomised Controlled Trial
- PC6 injection enhanced the preventive effect against postoperative nausea of granisetron compared with intravenous injection in gynecological laparoscopic patients: a randomized controlled study
- Delayed Umbilical Extrusion of a Ventriculoperitoneal Shunt Following Robotic-Assisted Laparoscopic Hysterectomy: A Case Report
BibTeX
@article{deng2026efficacy,
title = {{Efficacy of different doses of oliceridine for Patient-Controlled Intravenous Analgesia in patients undergoing Total Laparoscopic Hysterectomy}},
author = {Jiaojiao Deng and Baobao Ma and Kaihua Wei and Tao Wei and Liping Xie and Hong Zhang and Changxu Wang},
journal = {PLOS One},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0357372},
url = {https://doi.org/10.1371/journal.pone.0357372},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Efficacy of different doses of oliceridine for Patient-Controlled Intravenous Analgesia in patients undergoing Total Laparoscopic Hysterectomy
AU - Jiaojiao Deng
AU - Baobao Ma
AU - Kaihua Wei
AU - Tao Wei
AU - Liping Xie
AU - Hong Zhang
AU - Changxu Wang
PY - 2026
DA - 2026/09/03
JO - PLOS One
DO - 10.1371/journal.pone.0357372
UR - https://doi.org/10.1371/journal.pone.0357372
AB - Objective: To evaluate the efficacy and safety of three oliceridine different doses for oliceridine for patient-controlled analgesia (PCIA) in patients undergoing during total laparoscopic hysterectomy, following the premature termination of the planned sufentanil control arm. Methods: This prospective, randomized, double-blind trial was originally designed as a four-arm study. Due to operational challenges in patient recruitment and randomization within the single-center setting-specifically, significant reluctance among eligible patients to be randomized to receive a traditional opioid regimen when oliceridine was available, leading to unsustainable enrollment timelines—the sufentanil control arm was prematurely terminated. The final analysis therefore focused on three oliceridine doses: 0.1, 0.35, and 0.5 mg/kg, diluted to 100 ml with normal saline for 48-hour PCIA. The primary endpoint for sample size calculation was the incidence of postoperative nausea and vomiting (PONV) at 24 h. Efficacy and safety outcomes analyzed included: NRS pain scores (at rest and during cough), Ramsay sedation scores, incidence of rescue analgesia, various recovery indicators (time to first flatus, time to ambulation, QoR-15 scores), and opioid-related adverse events. Results: Compared to the low-dose group, the moderate- and high-dose groups demonstrated significant improvements in cough-pain scores and bolus press attempts (“Bolus press attempts” were defined as the total number of patient-initiated demands for a supplemental dose, including attempts made within the lockout interval) (p < 0.0083). Further comparison revealed that the moderate-dose group showed the best recovery outcomes, including shorter time to first flatus and ambulation, and higher QoR-15 scores. In contrast, although the high-dose group provided more potent analgesia, it was associated with a higher incidence of nausea, delayed flatus, and a significantly lower quality of recovery (QoR-15) score at 48 hours postoperatively compared to the moderate-dose group (p < 0.0083). Conclusion: Within the investigated PCA oliceridine dose range, the 0.35 mg/kg dose promotes early recovery in patients undergoing laparoscopic total hysterectomy through effective analgesia and reduced nausea, representing the best balance between efficacy and safety among the tested oliceridine-specific regimens.
SN - 1932-6203
ER -